T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease

RESEARCH TRIANGLE PARK, N.C. , April 20, 2021 / T3D Therapeutics, Inc. (“T3D”), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator T3D-959 in patients with mild to moderate Alzheimer’s disease, the PIONEER Study. Read Full Press Release Here

The release as fetched from its publisher. t3dtherapeutics.com ↗